{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:54:11Z","timestamp":1788267251014,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>\n                    <jats:bold>Background and Objective:<\/jats:bold>\n                    Sacubitril\/valsartan (SV) is an angiotensin receptor-neprilysin inhibitor that works by inhibiting the neprilysin enzyme as well as blocking angiotensin receptors. The benefits of using SV in congestive heart failure patients has been demonstrated in several clinical trials; however, limited data are available for dogs with heart failure. The aim of this study was to investigate the short-term effects of SV in comparison with ramipril in the standard therapy of symptomatic dogs suffering from myxomatous mitral valve disease (MMVD).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    In this prospective, randomized, single-blind study, 21 dogs with MMVD stage C were randomly assigned to received SV (20 mg\/kg orally twice a day) or ramipril (0.125 mg\/kg, orally once a day) in addition to pimobendan and furosemide. Echocardiography, electrocardiography, blood pressure, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and urinary aldosterone per creatinine ratio were obtained at baseline (D0) and at follow-up (4 weeks).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    When comparing the percent change from baseline between groups, the left atrium to aortic root ratio (LA\/Ao) and left ventricular internal diameter diastole normalized to body weight (LVIDDN) were significantly reduced in the SV group (\n                    <jats:italic>P<\/jats:italic>\n                    &amp;lt; 0.001 and\n                    <jats:italic>P<\/jats:italic>\n                    &amp;lt; 0.01, respectively). The end-diastolic volume index (EDVI), end-systolic volume index (ESVI), and stroke volume were lower in the SV group (\n                    <jats:italic>P<\/jats:italic>\n                    &amp;lt; 0.001,\n                    <jats:italic>P<\/jats:italic>\n                    &amp;lt; 0.05, and\n                    <jats:italic>P<\/jats:italic>\n                    &amp;lt; 0.01, respectively). No changes were observed between groups for NTproBNP, blood pressure, ECG parameters, and urinary aldosterone per creatinine ratio.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    The current study suggested that the short-term effects of SV can reverse myocardial remodeling, as inferred from several echocardiographic indices (i.e., the reduction in LA\/Ao, LVIDDN, EDVI and ESVI) in dogs with MMVD stage C. These findings would support the use of SV in clinically symptomatic heart failure in dogs.\n                  <\/jats:p>","DOI":"10.3389\/fvets.2021.700230","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T01:01:58Z","timestamp":1627347718000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Short-Term Effects of Sacubitril\/valsartan on Echocardiographic Parameters in Dogs With Symptomatic Myxomatous Mitral Valve Disease"],"prefix":"10.3389","volume":"8","author":[{"given":"Nakkawee","family":"Saengklub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prapawadee","family":"Pirintr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanida","family":"Nampimoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusak","family":"Kijtawornrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narongsak","family":"Chaiyabutr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jvc.2012.02.001","article-title":"Pathology of myxomatous mitral valve disease in the dog","volume":"14","author":"Fox","year":"2012","journal-title":"J Vet Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cvsm.2010.03.008","article-title":"Canine degenerative myxomatous mitral valve disease: Natural history, clinical presentation and therapy","volume":"40","author":"Borgarelli","year":"2010","journal-title":"Vet Clin North Am Small Anim Pract."},{"key":"B3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1939-1676.2007.0008.x","article-title":"Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease","volume":"22","author":"Borgarelli","year":"2008","journal-title":"J Vet Intern Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1939-1676.2002.tb01610.x","article-title":"Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation","volume":"16","author":"Kvart","year":"2002","journal-title":"J Vet Intern Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/jvim.15488","article-title":"ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs","volume":"33","author":"Keene","year":"2019","journal-title":"J Vet Intern Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jvc.2012.02.002","article-title":"Pharmacologic management of myxomatous mitral valve disease in dogs","volume":"14","author":"Atkins","year":"2012","journal-title":"J Vet Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics","volume":"34","author":"Mangiafico","year":"2013","journal-title":"Eur Heart J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1161\/hc0302.103593","article-title":"Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure","volume":"105","author":"Fielitz","year":"2002","journal-title":"Circulation."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/j.ddstr.2013.11.002","article-title":"Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure","volume":"9","author":"Langenickel","year":"2012","journal-title":"Drug Discov Today Ther Strateg."},{"key":"B10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2460\/javma.1995.206.02.194","article-title":"Vertebral scale system to measure canine heart size in radiographs","volume":"206","author":"Buchanan","year":"1995","journal-title":"J Am Vet Med Assoc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation","volume":"139","author":"Kang","year":"2019","journal-title":"Circulation."},{"key":"B13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1939-1676.2003.tb02430.x","article-title":"Brain natriuretic peptide concentration in dogs with heart disease and congestive heart failure","volume":"17","author":"MacDonald","year":"2003","journal-title":"J Vet Intern Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"B15","unstructured":"Assessment report: EntrestoEMA.2015"},{"key":"B16","doi-asserted-by":"publisher","first-page":"H1385","DOI":"10.1152\/ajpheart.1999.276.4.H1385","article-title":"Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure","volume":"276","author":"Tanimura","year":"1999","journal-title":"Am J Physiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1538\/expanim.18-0030","article-title":"Acute effect of ivabradine on heart rate and myocardial oxygen consumption in dogs with asymptomatic mitral valve degeneration","volume":"67","author":"Pirintr","year":"2018","journal-title":"Exp Anim."},{"key":"B18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0894-7317(89)80014-8","article-title":"Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms","volume":"2","author":"Schiller","year":"1989","journal-title":"J Am Soc Echocardiogr."},{"key":"B19","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/jvim.14586","article-title":"Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial","volume":"30","author":"Boswood","year":"2016","journal-title":"J Vet Intern Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr."},{"key":"B21","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1292\/jvms.16-0372","article-title":"Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration","volume":"79","author":"Kijtawornrat","year":"2017","journal-title":"J Vet Med Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.vascn.2004.03.013","article-title":"How many cardiac cycles must be measured to permit accurate RR, QT, and QTc estimates in conscious dogs?","volume":"50","author":"Hamlin","year":"2004","journal-title":"J Pharmacol Toxicol Methods."},{"key":"B23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0160-5402(89)90015-6","article-title":"An improved method to correct the QT interval of the electrocardiogram for changes in heart rate","volume":"22","author":"Van de Water","year":"1989","journal-title":"J Pharmacol Methods."},{"key":"B24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.21037\/cdt.2017.03.12","article-title":"Assessing observer variability: a user's guide","volume":"7","author":"Popovic","year":"2017","journal-title":"Cardiovasc Diagn Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1740-8261.2002.tb01051.x","article-title":"Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in cavalier King Charles spaniels with and without left atrial enlargement","volume":"43","author":"Hansson","year":"2002","journal-title":"Vet Radiol Ultrasound."},{"key":"B26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1939-1676.2004.tb02551.x","article-title":"Allometric scaling of M-mode cardiac measurements in normal adult dogs","volume":"18","author":"Cornell","year":"2004","journal-title":"J Vet Intern Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/jvim.15240","article-title":"A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril\/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease","volume":"32","author":"Newhard","year":"2018","journal-title":"J Vet Intern Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1016\/j.jacc.2018.07.102","article-title":"Sacubitril\/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits","volume":"72","author":"Torrado","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-Terminal Pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","author":"Januzzi","year":"2019","journal-title":"JAMA."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet."},{"key":"B31","doi-asserted-by":"publisher","first-page":"100418","DOI":"10.1016\/j.ijcha.2019.100418","article-title":"Impact of sacubitril\/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation","volume":"25","author":"Bayard","year":"2019","journal-title":"Int J Cardiol Heart Vasc."},{"key":"B32","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.107.749440","article-title":"Mitral leaflet adaptation to ventricular remodeling: occurrence and adequacy in patients with functional mitral regurgitation","volume":"118","author":"Chaput","year":"2008","journal-title":"Circulation."},{"key":"B33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jvc.2017.03.001","article-title":"Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease","volume":"19","author":"Ames","year":"2017","journal-title":"J Vet Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12917-020-02716-6","article-title":"Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease","volume":"17","author":"Galizzi","year":"2021","journal-title":"BMC Vet Res."}],"updated-by":[{"DOI":"10.3389\/fvets.2026.1832646","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000}}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2021.700230\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:55:16Z","timestamp":1776088516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2021.700230\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":34,"alternative-id":["10.3389\/fvets.2021.700230"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2021.700230","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,27]]},"article-number":"700230"}}